Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment / Edition 1

by Ashkan Emadi MD, PhD, Judith E. Karp MD

Overview

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults.

This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, ‘bite-sized’ text. The result is a visually engaging book that is easy to read, review, and remember.

Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment prools, this engaging format provides a unique and ‘go-to’ resource.

KEY FEATURES

• Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legends
• Presents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand format
• Provides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantation
• Includes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design process
• Includes digital access to the ebook as well as an online Image Bank

Product Details

ISBN-13:	9781620701003
Publisher:	Springer Publishing Company
Publication date:	07/17/2017
Pages:	376
Product dimensions:	7.00(w) x 10.20(h) x 1.20(d)

About the Author

Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.

Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.

Table of Contents

Contents

Contributors

Abbreviations

Preface

1. Epidemiology

Ashkan Emadi, Farin Kamangar, and Judith E. Karp

2. Diagnosis

Clinical Manifestations of Acute Leukemia

Daniel L. Duncan, Nathan D. Montgomery, Matthew C. Foster, and Joshua F. Zeidner

Pathology, Classification, and Methodologies

Histopathology

Zeba N. Singh and Qing C. Chen

Classification of AML

Zeba N. Singh and Qing C. Chen

Classification of ALL

Zeba N. Singh and Qing C. Chen

Classical Genetics

Ying Zou and Yi Ning

Modern Molecular Genetics

Parvez M. Lokhandwala and Christopher D. Gocke

Molecular Mutations in AML

Catherine Lai

FLT3

Mark J. Levis

C-KIT

Joshua F. Zeidner

Ras/Raf/MEK/ERK Pathways

Frank McCormick

NPM1

Alexander E. Perl

PI3K/AKT/mTOR Pathway

Mohamed Rahmani and Steven Grant

RUNX1

Chandrima Sinha, Lea C. Cunningham, and Paul P. Liu

MLL

Peter D. Aplan

CEBPa

Alan D. Friedman

GATA2

Dennis D. Hickstein

DNMT3A

Timothy J. Ley and David H. Spencer

TET and IDH

Amir T. Fathi

WT1

Sheenu Sheela, John Barrett, and Catherine Lai

ASXL1 and EZH2

Lizamarie Bachier-Rodriguez and Joseph M. Scandura

EVI1

Ling Li and Guido Marcucci

p53

Sami N. Malek

Secondary AML (s-AML)

R. Coleman Lindsley

MicroRNAs: Networks in Acute Leukemia

Lukasz P. Gondek and Gabriel Ghiaur

Prognostic Implication of Mutational Interplay

Ashkan Emadi and Judith E. Karp

Molecular Mutations in ALL

Kristen O’Dwyer and Anjali Advani

3. Therapy

Management of Early Crisis

Hyperleukocytosis

Heather J. Male and Tara Lin

Tumor Lysis and Cytokine Release Syndromes

Ashkan Emadi and Judith E. Karp

Febrile Neutropenia

Judith E. Karp

Treatment of AML in Adults

AML Treatment in Younger Patients

Joshua F. Zeidner and Matthew C. Foster

AML Treatment in Older Patients

Houman Nourkeyhani and Eunice S. Wang

Treatment of Relapsed/Refractory AML

Mark R. Litzow and Selina M. Luger

Acute Promyelocytic Leukemia (APL)

Aziz Nazha, Steven D. Gore, and Amer Methqal Zeidan

MDS/AML

Fundamentals of Epigenetics

Monica Reddy Muppidi, Priyank P. Patel, Adam R. Karpf, and Elizabeth A. Griffiths

Clonal Evolution and Treatment of Secondary AML and MDS/AML

Vu H. Duong and Amer Methqal Zeidan

Treatment of ALL in Adults

Matthew J. Wieduwilt

Risk Stratification

General Therapeutic Principles

Relapsed/Refractory ALL

Conclusion

Treatment of AML in Children/Adolescents

Jessica Knight-Perry and Lia Gore

De Novo AML

APML

AML With Trisomy 21

Relapsed/Refractory AML

Common Complications and Supportive Care

Indication for Allogeneic Stem Cell Transplant

Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma: Epidemiology, Survival Trends, and Optimal Therapy

Archie Bleyer

Treatment of ALL in Children and Adolescents

Susan R. Rheingold and Stephen P. Hunger

Prognostic Indicators/Risk Stratification

ALL Therapy

Radiation Therapy

Outcome

Infant ALL

Down Syndrome-Associated ALL

Philadelphia Chromosome Positive (Ph+) and Philadelphia Chromosome-Like ALL

Targeted Therapies

Relapsed/Refractory ALL

Indications for Allogeneic Stem Cell Transplant

4. Allogeneic Transplant in Adults and Children for AML and ALL

Allen R. Chen, Gordon Cohen, Sawa Ito, Heather Symons, and Nancy M. Hardy

5. Measurable (Minimal) Residual Disease

The Mechanics of Quantized Hematopoiesis

Michael R. Loken

Fundamentals of Quantitative Antigen Expression

Maturation in Hematopoiesis is Characterized by Quantized Steps

Neoplastic Transformation Results in Disruption of Maturation

Summary

Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL): An Important Prognostic Indicator and Efficacy/Response Biomarker in Children and Adults

Gregory H. Reaman and Franklin O. Smith III

Clinical Significance of MRD Detection

Role of MRD as a Drug Development Tool in ALL

Sequence-Specific MRD for ALL

Aaron C. Logan

Measurable Residual Disease for AML

Christopher S. Hourigan and Aaron C. Logan

6. Psychosexual Aspects of Management of Acute Leukemia

Nancy Corbitt and Trisha Kendall

7. Chemotherapeutic Agents for Treatment of AML and ALL

Ashkan Emadi, Noa G. Holtzman, Matthew J. Wieduwilt, and Judith E. Karp

8. New Therapeutic Targets for Acute Leukemia

Stem Cells

Craig T. Jordan and Daniel A. Pollyea

Exploiting the DNA Damage Response and Repair Pathways

Ivana Gojo, Keith W. Pratz, and Judith E. Karp

Poly(ADP-Ribose) Polymerase (PARP): An Intriguing Molecular Target for Leukemia

Targeting Tumor Metabolism for Treatment of Acute Leukemia

Firas El Chaer and Ashkan Emadi

Mechanisms of Drug Resistance in Acute Leukemia

Maria R. Baer

Microenvironment

Gabriel Ghiaur and Pamela S. Becker

Immunology

Hanna A. Knaus, Raúl Montiel Esparza, and Ivana Gojo

9. Regulatory Considerations for the Practitioner

Donna Przepiorka and Ann T. Farrell

Index

Editorial Reviews

Reviewer: Ravi Salgia, MD, PhD (City of Hope)
Description: This review was co-written by Prakash Kulkarni, PhD (City of Hope National Medical Center)
As the title suggests, this is a concise, visual guide to the diagnosis and treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), two hematological malignancies that are more common in children than in adults.
Purpose: The purpose is to present complex information about AML and ALL in a visually instructive format that is easily digestible.
Audience: This illustrated book is a resource not only for clinicians actively treating patients but also for early-stage medical professionals, students, and scientists involved in leukemia research. Each chapter is contributed by clinicians and scientists who are experts in their respective fields.
Features: The chapters are well organized under nine different subheadings ranging from epidemiology to regulatory considerations addressing all aspects of AML and ALL, including risk factors, cytogenetics, mutations, diagnoses, management and prognoses. Unlike a typical textbook or reference, the book relies on a visual rather than a narrative format to present complex information so that it is easy to follow and understand. The extensive use of illustrations, pictures, and tables helps keep readers engaged. The experience could have been enhanced had the publisher used a higher quality, glossy paper, but the book includes access to an ebook version with an online image bank.
Assessment: This is a unique presentation of the must-know information when encountering AML and ALL patients who require immediate attention.

Doody's Review Service